NTLA
Intellia Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.58B
P/E Ratio
—
EPS
$-3.81
Beta
1.93
52W High
$28.25
52W Low
$6.83
50-Day MA
$13.62
200-Day MA
$13.16
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.10
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $67.67M |
| Gross Profit (TTM) | $-256.78M |
| EBITDA | $-431.22M |
| Operating Margin | -428.90% |
| Return on Equity | -53.50% |
| Return on Assets | -27.10% |
| Revenue/Share (TTM) | $0.62 |
| Book Value | $5.77 |
| Price-to-Book | 2.35 |
| Price-to-Sales (TTM) | 23.30 |
| EV/Revenue | 18.0 |
| EV/EBITDA | -5.51 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 78.80% |
| Shares Outstanding | $118.93M |
| Float | $111.94M |
| % Insiders | 4.10% |
| % Institutions | 75.88% |
Historical Volatility
HV 10-Day
111.89%
HV 20-Day
87.40%
HV 30-Day
82.59%
HV 60-Day
78.23%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($26.80 target)
1
Strong Buy13
Buy9
Hold1
Sell1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/5/2026